Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Azenta Inc(AZTA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AZTA
09/28/2026: AZTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Azenta Inc is a specialized life science tools provider focused on automated sample management and genomic services. By transitioning from its legacy as a semiconductor automation provider, the company has established a leading position in the essential cold-chain logistics market. Its primary growth story involves capitalizing on the surge in biopharmaceutical research and the trend toward outsourcing genomic analysis. However, it faces risks from significant competition by diversified global conglomerates and the inherent volatility of R&D budgets. Azenta is best suited for growth-oriented investors who can tolerate market fluctuations, provided that the company demonstrates successful integration of its acquisitions and maintains consistent operational execution.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is positioned to benefit from secular growth trends in biopharma R&D and genomic research. |
| Momentum investor | Mixed fit | Momentum depends on sustained sector outperformance and evidence of successful M&A integration. |
| Value investor | Weak fit | Current valuation reflects growth expectations rather than discounted cash flows. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses capital on growth. |
| Low-risk investor | Weak fit | The stock exhibits volatility common to mid-cap growth stocks in the life sciences sector. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | As a growth-oriented stock, it is subject to broader market sentiment regarding biopharma spending. |
| Valuation risk | Medium | The stock's premium is predicated on consistent execution of growth targets. |
| Competition risk (Consolidated giants) | High | Large incumbents like Thermo Fisher can bundle services, creating significant competitive pressure. |
| Business quality | Medium | The transition to a pure-play life sciences company is ongoing, with historical semiconductor roots influencing the current structure. |
| Dividend income | Low / none | Investors seeking income will not find value here due to the lack of dividend payments. |
| Execution risk | Medium | The strategy relies on the successful integration of multiple distinct acquisitions to achieve operational synergies. |
Price Behavior
Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -27.82% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.49B USD | Price to earnings Ratio - | 1Y Target Price 35.25 |
Price to earnings Ratio - | 1Y Target Price 35.25 | ||
Volume (30-day avg) 839.1K shares | Beta 1.39 | 52 Weeks Range 15.93 - 41.73 | Updated Date 09/27/2026 |
52 Weeks Range 15.93 - 41.73 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.47 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Life Sciences Products | Automated cryogenic storage and biological sample management hardware. | The company sells the specialized 'freezers' and robotic systems that keep vital biological research samples safe. |
| Life Sciences Services | Genomic sequencing, synthesis, and clinical sample processing services. | The company performs the laboratory work and data analysis that scientists need to develop new drugs. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 29.07 | Enterprise Value 1.22B | Price to Sales(TTM) 2.43 |
Enterprise Value 1.22B | Price to Sales(TTM) 2.43 | ||
Enterprise Value to Revenue 1.99 | Enterprise Value to EBITDA 37.14 | Shares Outstanding 43.81M | Shares Floating 38.88M |
Shares Outstanding 43.81M | Shares Floating 38.88M | ||
Percent Insiders 1.36 | Percent Institutions 117.26 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Azenta Inc
Exchange NASDAQ | Headquarters Burlington, MA, United States | ||
IPO Launch date 1995-02-02 | Interim President, CEO & Director Dr. Martin D. Madaus D.V.M., Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 2900 | Website https://www.azenta.com |
Full time employees 2900 | Website https://www.azenta.com | ||
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.